Equities Analysts Set Expectations for Neurogene Q1 Earnings

Neurogene Inc. (NASDAQ:NGNE) – Analysts at HC Wainwright raised their Q1 2026 earnings estimates for Neurogene in a report released on Thursday, March 26th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($1.00) per share for the quarter, up from their prior forecast of ($1.04). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. HC Wainwright also issued estimates for Neurogene’s Q2 2026 earnings at ($1.02) EPS, Q3 2026 earnings at ($1.05) EPS, Q4 2026 earnings at ($1.08) EPS and FY2026 earnings at ($4.16) EPS.

NGNE has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, January 22nd. Canaccord Genuity Group assumed coverage on Neurogene in a report on Friday, February 27th. They issued a “buy” rating for the company. Wall Street Zen lowered Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, Lifesci Capital started coverage on shares of Neurogene in a research note on Monday, January 26th. They set an “outperform” rating and a $50.00 price objective on the stock. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.00.

Neurogene Stock Performance

NASDAQ NGNE opened at $20.35 on Monday. The stock has a 50-day simple moving average of $19.52 and a two-hundred day simple moving average of $21.69. The firm has a market capitalization of $316.85 million, a P/E ratio of -4.80 and a beta of 1.53. Neurogene has a fifty-two week low of $6.88 and a fifty-two week high of $37.27.

Neurogene (NASDAQ:NGNE) last posted its earnings results on Tuesday, March 24th. The company reported ($1.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.08.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its position in shares of Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after buying an additional 978 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Neurogene by 24.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock worth $88,000 after acquiring an additional 1,000 shares in the last quarter. ADAR1 Capital Management LLC increased its holdings in Neurogene by 3.4% in the 3rd quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock worth $531,000 after acquiring an additional 1,008 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after acquiring an additional 1,059 shares during the period. Finally, Daiwa Securities Group Inc. purchased a new position in Neurogene during the fourth quarter valued at $66,000. 52.37% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Neurogene

In related news, insider Stuart Cobb sold 6,797 shares of the company’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $20.81, for a total value of $141,445.57. Following the completion of the transaction, the insider owned 30,497 shares of the company’s stock, valued at approximately $634,642.57. This represents a 18.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Christine Mikail Cvijic sold 4,045 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $20.81, for a total value of $84,176.45. Following the transaction, the chief financial officer owned 105,798 shares in the company, valued at $2,201,656.38. This represents a 3.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 9.92% of the stock is owned by company insiders.

Key Stories Impacting Neurogene

Here are the key news stories impacting Neurogene this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and set a $70 price objective for NGNE, providing bullish analyst support even as it modeled FY2027 EPS of ($4.93). This endorsement and high target can help underpin longer-term upside. HC Wainwright Buy/$70 Target
• Positive Sentiment: An MSN/aggregated report flagged a substantial analyst-driven price-target increase (reported as a 37.29% rise to 82.62), signaling at least one firm is materially more optimistic on Neurogene’s longer-term value — a clear positive for investor sentiment and potential catalyst for upside. Neurogene (NGNE) price target increased by 37.29% to 82.62
• Neutral Sentiment: A Globe and Mail roundup included Neurogene in a broader analysts-insights piece; such coverage can raise visibility but didn’t add new company-specific data likely to move the stock by itself. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Lifesci Capital cut Q1–Q4 2026 and FY2026 EPS estimates for NGNE across multiple notes, lowering FY2026 EPS to ($4.59) (from $4.33) while still keeping an “Outperform” rating and a $50 target. Those downward revisions to near-term profitability are a bearish driver and likely the primary reason for today’s weakness. Lifesci Capital EPS revisions / Outperform $50

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.